Physician profile
Corey A Jaquez
NPI 1205073962
$4,721.81
in general payments reported to CMS, 2019-2025
24 companies · $908 in 2025
The $908 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,282 · 2020: $102 · 2021: $14.07 · 2022: $78.71 · 2023: $960 · 2024: $1,377 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,176 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,176.26 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $859.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $829.93 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $628.36 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $489.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $450.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $227.42 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $211.28 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.17 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $145.00 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $138.47 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Novartis Pharmaceuticals Corporation | $111.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $74.09 | 2019 | |
| Amgen INC. | $68.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $66.15 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.72 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $48.75 | 2019 | |
| Abbott Laboratories | $24.44 | 2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $23.03 | 2025 | The Cologuard Plus Collection Kit |
| Kaleo, INC. | $21.50 | 2023 | Auvi-Q |
| Otsuka America Pharmaceutical, INC. | $20.09 | 2024 | Rexulti |
| Ironwood Pharmaceuticals, INC | $18.43 | 2019 | |
| Phadia US INC. | $15.71 | 2019 | |
| Horizon Therapeutics Plc | $14.13 | 2019 | |
| Amarin Pharma, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Jaquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.